Maintaining focus on MoCD Type A
Though molybdenum cofactor deficiency (MoCD) Type A is considered a rare disorder, it is anything but rare to those whose lives are affected by it. Understanding the negative impact of sulfite intoxication and, more specifically, MoCD Type A, is improving every day, with information available from a variety of sources, including Origin Biosciences and its parent company, BridgeBio.
Learn more about clinical trials
Participating in clinical trials offers the opportunity for treatment with novel agents being investigated. These trials may offer hope for treatment advancements, and findings from these studies can be used to help other patients.
A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 in Neonates, Infants, and Children With MoCD Type A is currently recruiting.1*
- The safety and efficacy of fosdenopterin hydrobromide have not been established. There is no guarantee that fosdenopterin hydrobromide will receive health authority approval or become commercially available in any country for the uses being investigated.
The latest news from Origin and BridgeBio
Press releases and updates on late-breaking research and other relevant news from inside Origin Biosciences and our parent company, BridgeBio.
BridgeBio Pharma’s Origin Biosciences Presents New Data On The Natural History Of Molybdenum Cofactor Deficiency (MoCD) Type A At The Society Of The Study Of Inborn Errors Of Metabolism (SSIEM) Conference
Take action immediately.
Call (617) 322-5165
- National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02629393?cond=mocd&draw=2&rank=1. Accessed September 25, 2020.